AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data –...